(Q34671647)

3 August 2017

1 reference

title

Particular aspects of platinum compounds used at present in cancer treatment (English)

1 reference

3 August 2017

1 reference

Bernard Desoize

1

1 reference

PubMed ID

12050023

3 August 2017

Claudie Madoulet

series ordinal

2

1 reference

3 August 2017

1 June 2002

1 reference

Critical Reviews in Oncology Hematology

3 August 2017

1 reference

3 August 2017

42

1 reference

3 August 2017

3

1 reference

3 August 2017

317-325

1 reference

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

DNA Adducts of cis-Diamminedichloroplatinum(II) and Its Trans Isomer Inhibit RNA Polymerase II Differentially in Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Cisplatin and DNA repair in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in HeLa cells treated with cis-diamine(glycolato)platinum(II).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Preclinical perspectives on platinum resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Individual dose adaptation of anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Clinical studies of reversal of drug resistance based on glutathione.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Overexpression of metallothionein confers resistance to anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Mechanisms of resistance to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Ongoing and unsaid on oxaliplatin: the hope

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Multicellular resistance: a paradigm for clinical resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Chemical reactivity of cisplatin bound to human plasma proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Clinical pharmacokinetics and administration of established platinum drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Oxaliplatin: pharmacokinetics and chronopharmacological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Oxaliplatin in practice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900219-0

7 January 2021

10.1016/S1040-8428(01)00219-0

Identifiers

DOI

1 reference

release_3acz7tyaezaaphbj3ah2pcb6sy

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3acz7tyaezaaphbj3ah2pcb6sy

24 November 2022

mapped directly with Wikidata item

PubMed ID

12050023

1 reference

PubMed ID

12050023